| Autor: |
Keyzor I; Amicus Therapeutics Ltd., Marlow SL7 1HZ, UK., Shohet S; Amicus Therapeutics Ltd., Marlow SL7 1HZ, UK., Castelli J; Amicus Therapeutics Inc., Princeton, NJ 08542, USA., Sitaraman S; Amicus Therapeutics Inc., Princeton, NJ 08542, USA., Veleva-Rotse B; Amicus Therapeutics Inc., Princeton, NJ 08542, USA., Weimer JM; Amicus Therapeutics Inc., Philadelphia, PA 19104, USA., Fox B; Amicus Therapeutics Inc., Princeton, NJ 08542, USA., Willer T; Amicus Therapeutics Inc., Philadelphia, PA 19104, USA., Tuske S; Amicus Therapeutics Inc., Philadelphia, PA 19104, USA., Crathorne L; Prescript Communications Ltd., Letchworth Garden City SG6 3TA, UK., Belzar KJ; Prescript Communications Ltd., Letchworth Garden City SG6 3TA, UK. |
| Abstrakt: |
The treatment landscape for lysosomal storage disorders (LSDs) is rapidly evolving. An increase in the number of preclinical and clinical studies in the last decade has demonstrated that pharmacological chaperones are a feasible alternative to enzyme replacement therapy (ERT) for individuals with LSDs. A systematic search was performed to retrieve and critically assess the evidence from preclinical and clinical applications of pharmacological chaperones in the treatment of LSDs and to elucidate the mechanisms by which they could be effective in clinical practice. Publications were screened according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) reporting guidelines. Fifty-two articles evaluating 12 small molecules for the treatment of seven LSDs are included in this review. Overall, a substantial amount of preclinical and clinical data support the potential of pharmacological chaperones as treatments for Fabry disease, Gaucher disease, and Pompe disease. Most of the available clinical evidence evaluated migalastat for the treatment of Fabry disease. There was a lack of consistency in the terminology used to describe pharmacological chaperones in the literature. Therefore, the new small molecule chaperone (SMC) classification system is proposed to inform a standardized approach for new, emerging small molecule therapies in LSDs. |
